首页/数据集/Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NIAID Data Ecosystem2026-03-14 收录

IB/IIA期临床试验

癌症联合疗法

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2745148 数据链接链接失效反馈

官方服务：

资源简介：

A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.

应用场景：

创建时间：

2022-11-15

多发性骨髓瘤药物响应与抗性

癌症联合疗法

Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes mye

NIAID Data Ecosystem50

MMS induced expression changes and the effect of sorafenib

癌症联合疗法

烷化损伤应答

Despite the high toxicity, alkylating agents are still at the forefront of several clinical protocols used to treat cancers. In this study, we investigated the mechanisms underlying alkylation damage

NIAID Data Ecosystem30

Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1.

癌症联合疗法

纳米药物递送

Rhabdomyosarcoma (RMS) is a highly metastatic soft-tissue sarcoma that often develops resistance to current therapies, including vincristine. Since the existing treatments have not significantly impro

NIAID Data Ecosystem00

Synergy analysis for ETO-Cur and TRF combination therapy in colon cancer cells.

癌症联合疗法

结肠癌药物研究

Synergy analysis for ETO-Cur and TRF combination therapy in colon cancer cells.

NIAID Data Ecosystem50

Combination of anlotinib and Tislelizumab for lung adenocarcinoma: effects on Transcriptome

癌症联合疗法

转录组学分析

To explore the specific mechanism of action of the immune checkpoint inhibitor tislelizumab in combination with anlotinib in the treatment of lung adenocarcinoma from the perspective of transcriptomic

NIAID Data Ecosystem30

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

资源简介：

相关数据集